Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-871-2098
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$207.74 million
Profitability
Miscellaneous
Employees113
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.64) by $0.18. The biopharmaceutical company earned $53.17 million during the quarter, compared to the consensus estimate of $39.71 million. Akebia Therapeutics had a negative net margin of 69.12% and a negative return on equity of 49.78%. View Akebia Therapeutics' Earnings History.
When is Akebia Therapeutics' next earnings date?
What price target have analysts set for AKBA?
6 analysts have issued 12 month price targets for Akebia Therapeutics' stock. Their predictions range from $9.00 to $22.00. On average, they expect Akebia Therapeutics' share price to reach $15.1429 in the next twelve months. This suggests a possible upside of 125.7% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.
What is the consensus analysts' recommendation for Akebia Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.
What are Wall Street analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/1/2019)
- 2. Mizuho analysts commented, "We expect Akebia to compete with two other products within next-generation (HIF-PHI) anemia drugs and we believe order of market entry will be; 1) Fibrogen (FGEN, Buy, $74 PT)’s roxadustat, 2) Akebia’s vadadustat, and 3) GlaxoSmithKline (GSK, Not-rated)’s daprodustat, which we think is ~ 6 months behind vadadustat." (12/4/2018)
Has Akebia Therapeutics been receiving favorable news coverage?
Media stories about AKBA stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akebia Therapeutics earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Reata Pharmaceuticals (RETA), Insmed (INSM), Portola Pharmaceuticals (PTLA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), The Medicines (MDCO) and Uniqure (QURE).
What other stocks do shareholders of Akebia Therapeutics own?
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- Mr. John P. Butler, CEO, Pres & Director (Age 55)
- Mr. Michel Dahan, Sr. VP & Chief Bus. Officer (Age 40)
- Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
- Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
- Ms. Nicole R. Hadas, Sr. VP, Gen. Counsel & Sec. (Age 46)
Who are Akebia Therapeutics' major shareholders?
Akebia Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Strs Ohio (0.04%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.
Which institutional investors are buying Akebia Therapeutics stock?
How do I buy shares of Akebia Therapeutics?
Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of AKBA stock can currently be purchased for approximately $6.71.
How big of a company is Akebia Therapeutics?
Akebia Therapeutics has a market capitalization of $785.88 million and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 113 workers across the globe.
What is Akebia Therapeutics' official website?
How can I contact Akebia Therapeutics?
Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]
MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
